(January 23, 2018, 1:38 PM EST) -- WASHINGTON, D.C. — An ex parte re-examination by the Patent Trial and Appeal Board that resulted in the rejection of seven claims of the patented immunosuppressive drug Remicade was not erroneous, the Federal Circuit U.S. Court of Appeals ruled Jan. 23, upholding findings of obviousness-type double patenting (In re: Janssen Biotech Inc., et al., No. 17-1257, Fed. Cir.)....